ORIC Pharmaceuticals
Advances two Phase 3 oncology candidates targeting drug-resistant prostate and lung cancers.
$13.24
After-hours close+0.01 (+0.08%)
At close$13.23(−3.71%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 120.70%Insiders 1.04%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 103.52M · Float 48.71M · 47.1% free float
Institutions13F, as of Jun 30, 2026
189 holders · 124.95M shares · 33 new positions · 113 increased · 44 reduced · 32 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Nextech Invest, Ltd. | 7.16M | 6.92% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 6.82M | 6.59% | +839.4K | Aug 7, 2026 |
| Ecor1 Capital, LLC | 6.73M | 6.50% | 0 | Aug 14, 2026 |
| Price T Rowe Associates Inc /MD/ | 6.62M | 6.39% | +1.23M | Aug 14, 2026 |
| Viking Global Investors LP | 5.13M | 4.95% | −697.8K | Aug 14, 2026 |
| State Street Corp | 4.89M | 4.73% | +1.19M | Aug 7, 2026 |
| Sr One Capital Management, LP | 4.62M | 4.46% | +100.5K | Aug 12, 2026 |
| VR Adviser, LLC | 4.32M | 4.17% | 0 | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Nextech Crossover I GP S.a. r.l. | 8.40% | 7.16M | 13G | Aug 14, 2025 ↗ |
| Viking Global Investors LP | 7.80% | 8.26M | 13G | May 15, 2026 ↗ |
| EcoR1 Capital, LLC | 6.90% | 6.73M | 13G | Aug 5, 2025 ↗ |
| BlackRock, Inc. | 5.60% | 5.47M | 13G | Jan 21, 2026 ↗ |
| T. Rowe Price Associates, Inc. | 5.40% | 5.39M | 13G | May 15, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Jacob Chacko | director, officer: PRESIDENT AND CEO | 581.7K | 0.56% | Dec 17, 2025 |
| Richard A. Heyman | director | 245.0K | 0.24% | Jul 28, 2026 |
| Lori Anne Kunkel | director | 84.2K | 0.08% | Dec 9, 2025 |
| Dominic Piscitelli | officer: Chief Financial Officer | 69.8K | 0.07% | Aug 28, 2026 |
| Pratik S. Multani | officer: Chief Medical Officer | 68.1K | 0.07% | Dec 17, 2025 |
| Angie You | director | 28.0K | 0.03% | Jun 23, 2025 |
1 ten-percent owner holds 1.10M shares by Form 4, outside the officers-and-directors figure above · 5 people have not refiled in the last 18 months (13.42M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 26, 2026 | Dominic Piscitelliofficer: Chief Financial Officer | Sale | 77,000 | $13.69 | 69,828 |
| Jul 24, 2026 | Richard A. Heymandirector | Sale · 2 lots | 13,100 | $12.02 | 244,972 |
| Jul 6, 2026 | Richard A. Heymandirector | Sale | 300 | $12.00 | 212,772 |
| Feb 24, 2026 | Dominic Piscitelliofficer: Chief Financial Officer | Sale | 52,000 | $13.51 | 68,148 |
| Jan 16, 2026 | Richard A. Heymandirector | Sale · 2 lots | 6,700 | $12.00 | 254,872 |
| Dec 16, 2025 | Jacob Chackodirector, officer: PRESIDENT AND CEO | Sale | 33,374 | $9.06 | 581,711 |
| Dec 16, 2025 | Dominic Piscitelliofficer: Chief Financial Officer | Sale | 10,720 | $9.06 | 68,148 |
| Dec 16, 2025 | Pratik S. Multaniofficer: Chief Medical Officer | Sale | 10,720 | $9.06 | 68,149 |
| Oct 6, 2025 | Jacob Chackodirector, officer: PRESIDENT AND CEO | Sale | 37,461 | $12.32 | 531,419 |
| Oct 6, 2025 | Dominic Piscitelliofficer: Chief Financial Officer | Sale | 11,000 | $14.52 | 48,317 |
CongressHouse and Senate disclosures
Not reported.